FOLH1 and neoplasm: Fung et al.[32] observed differences in the clearance rates of radioactivity from the tumor for two forms of the humanized monoclonal antibody J591 ([124I]I-J591 and [89Zr]Zr-J591) against prostate-specific membrane antigen (PSMA) in mice with LNCaP tumors.